TargetMol

Pasireotide Acetate

Product Code:
 
TAR-TP2207
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP2207-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2207-5mg5mg£431.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2207-10mg10mg£600.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2207-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP2207-50mg50mg£1,187.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pasireotide Acetate is a stable cyclohexapeptide somatostatin mimic
CAS:
396091-76-2
Formula:
C60H70N10O11
Molecular Weight:
1107.279
Pathway:
GPCR/G Protein
Purity:
0.9987
SMILES:
CC(O)=O.[H][C@@]1(CN2C(=O)[C@]([H])(Cc3ccccc3)N=C(O)[C@]([H])(Cc3ccc(OCc4ccccc4)cc3)N=C(O)[C@]([H])(CCCCN)N=C(O)[C@@]([H])(Cc3c[nH]c4ccccc34)N=C(O)[C@@]([H])(N=C(O)[C@]2([H])C1)c1ccccc1)OC(O)=NCCN
Target:
Somatostatin

References

Zhao Z, Gong F, Duan L, et al. Somatostatin receptor ligands suppressed proliferation and lipogenesis in 3T3?L1 preadipocytes. Basic & Clinical Pharmacology & Toxicology. 2022 Allen P J . Pasireotide for postoperative pancreatic fistula.[J]. New England Journal of Medicine, 2014, 371(9):875. Chakrabarti J, Pandey R, Churko J M, et al. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing?s Disease. Cells. 2022, 11(21): 3344. Coopmans E C , Muhammad A , Van d L A J , et al. How to Position Pasireotide LAR Treatment in Acromegaly[J]. Journal of Clinical Endocrinology & Metabolism, 2019, 104(6):1978-1988. Mallick S, Chakrabarti J, Eschbacher J, et al.Genetically Engineered Human Pituitary Corticotroph Tumor Organoids Exhibit Divergent Responses To Glucocorticoid Receptor Modulators.Translational Research.2023